Hepatitis C Drug Head-To-Head Comparative Studies Debated At PCORI Workshop
This article was originally published in The Pink Sheet Daily
Executive Summary
There appeared to be support for the idea that if head-to-head studies are funded, they should focus on “high risk populations,” such as intravenous drug users.
You may also be interested in...
Target's NASH Study Captures Real World Data, Helps Partners With Trial Design
Longitudinal observational study of NASH patients provides data to companies to help them better understand disease; Target PharmaSolutions conducting similar efforts in primary biliary cholangitis, hepatocellular carcinoma, and inflammatory bowel disease.
PCORI To Solicit More Head-To-Head Comparative Studies
The Patient-Centered Outcomes Research Institute announces plans to encourage the submission of more proposals for head-to-head clinical comparative effectiveness studies. Among the research topics the institute will encourage are the Institute of Medicine’s top 100 priorities and recommendations from America’s Health Insurance Plans.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.